Connell Louise C, Harding James J, Abou-Alfa Ghassan K
Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA.
Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA.
Curr Treat Options Oncol. 2016 Aug;17(8):43. doi: 10.1007/s11864-016-0415-3.
Hepatocellular carcinoma is a common malignancy worldwide, rapidly rising in incidence. While there have been some developments in advancing therapeutic options in this disease, these have admittedly been modest to date, and as a result, this is a patient population with an inherently poor prognosis. Currently, sorafenib remains the only established systemic therapy proven to increase the overall survival of patients with advanced disease. The approval of sorafenib in 2007 ushered in the era of targeted therapies. Several phase 2 and 3 clinical trials have failed however to improve on sorafenib in the first-line setting, and no single agent has been demonstrated to impact outcomes after sorafenib failure. Having reached somewhat of an impasse in terms of drug development in hepatocellular carcinoma, enthusiasm in the field has moved toward innovative approaches such as molecular characterization and immunotherapy in an attempt to impact survival. This review highlights the current endeavors in terms of experimental research for patients with advanced hepatocellular carcinoma.
肝细胞癌是全球常见的恶性肿瘤，发病率迅速上升。尽管在推进该疾病的治疗选择方面取得了一些进展，但迄今为止这些进展实属有限，因此，这是一个预后天生较差的患者群体。目前，索拉非尼仍然是唯一被证实可提高晚期疾病患者总生存期的既定全身治疗药物。2007年索拉非尼获批开启了靶向治疗时代。然而，多项2期和3期临床试验未能在一线治疗中超越索拉非尼，并且没有单一药物被证明在索拉非尼治疗失败后能影响治疗结果。在肝细胞癌药物研发方面已陷入某种僵局的情况下，该领域的热情已转向分子特征分析和免疫治疗等创新方法，试图影响生存率。本综述重点介绍了目前针对晚期肝细胞癌患者进行的实验研究工作。
